AAAAAA

   
Results: 1-14 |
Results: 14
TREATMENT OF BENIGN PROSTATIC HYPERPLASIA - A PHARMACOECONOMIC PERSPECTIVE
Authors: ERI LM TVETER KJ
Citation: Lm. Eri et Kj. Tveter, TREATMENT OF BENIGN PROSTATIC HYPERPLASIA - A PHARMACOECONOMIC PERSPECTIVE, Drugs & aging, 10(2), 1997, pp. 107-118
MORPHOMETRY OF BENIGN PROSTATIC HYPERPLASIA DURING ANDROGEN SUPPRESSIVE THERAPY - RELATIONSHIPS AMONG EPITHELIAL CONTENT, PSA DENSITY, AND CLINICAL OUTCOME
Authors: SVINDLAND A ERI LM TVETER KJ
Citation: A. Svindland et al., MORPHOMETRY OF BENIGN PROSTATIC HYPERPLASIA DURING ANDROGEN SUPPRESSIVE THERAPY - RELATIONSHIPS AMONG EPITHELIAL CONTENT, PSA DENSITY, AND CLINICAL OUTCOME, Scandinavian journal of urology and nephrology, 30, 1996, pp. 113-117
EFFECTS ON THE ENDOCRINE SYSTEM OFLONG-TERM TREATMENT WITH THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Authors: ERI LM HAUG E TVETER KJ
Citation: Lm. Eri et al., EFFECTS ON THE ENDOCRINE SYSTEM OFLONG-TERM TREATMENT WITH THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, Scandinavian journal of clinical & laboratory investigation, 56(4), 1996, pp. 319-325
ALPHA-BLOCKADE IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA - REPLY
Authors: ERI LM TVETER KJ
Citation: Lm. Eri et Kj. Tveter, ALPHA-BLOCKADE IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA - REPLY, The Journal of urology, 156(1), 1996, pp. 184-185
EFFECTS OF THE NONSTEROIDAL ANTIANDROGEN CASODEX ON LIPOPROTEINS, FIBRINOGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Authors: ERI LM URDAL P
Citation: Lm. Eri et P. Urdal, EFFECTS OF THE NONSTEROIDAL ANTIANDROGEN CASODEX ON LIPOPROTEINS, FIBRINOGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, European urology, 27(4), 1995, pp. 274-279
CAN FINASTERIDE REVERSE THE PROGRESS OF BENIGN PROSTATIC HYPERPLASIA - A 2-YEAR PLACEBO-CONTROLLED STUDY
Authors: ANDERSEN JT EKMAN P WOLF H BEISLAND HO JOHANSSON JE KONTTURI M LEHTONEN T TVETER K BODKER A VEDEL O NORDLING J POULSEN AL SCHOU J HVIDT V HANSEN JB MEYHOFF HH ELDRUP J HARTWELL D COLSTRUP H LYNGDORF P NIELSEN AH LARSEN E WALTER S LARSEN EH THYBO E MOMMSEN S BROK KE PALM L GENSTER H ANDERSEN M KAUPPINEN P RAUVALA M HAKKINEN J TAMMELA T TAINIO H HYNNINEN O TIITINEN J LEHTORANTA K ALAOPAS M PERTTILA I PETAS A RINTALA E SALMINEN R JUUSELA H HANSSON E VONWENDT R TUHKANEN K TALJA M NURMI M PUNTALA P PERMI J PUOLAKKA VM VIITANEN J GISLASON T EINARSSON GV ERI LM KARLSEN S HOLME P SIVERTSEN SM STEINSVIK E SERVOLL E URNES T MALME PA JOHANSEN TEB OMLAND H NAGELHUS J KLOSTER SE SKJEGGESTAD O VADA K MORTENSEN R NYBERG G PETTERSSON G WEDMAN L BRATELL S FOLMERZ P ZACKRISSON B DAHLGREN K TILLEGARD A AUS G BERGDAHL S HUGOSSON J HOLMQUIST B EK A RADEMARK C KRISTIANSEN P HERMANSSON CG PEDERSEN K OSCARSSON C KIHL B OLSSON JO NELVIN L LEISSNER KH LUNDSTAM S HJERTBERG H VARENHORST E ANDERSSON SO WINDAHL T SWARTZ R AHLBERG B GEDDA S ANDERSTROM C EDDELAND S HANSSON R STROGERG P ADOLFSSON J BAUER P KLEIST H STORM B RANCH T STRAVSNES H BREKKAN E EKLUND T KARLBERG L MALICE MP BRONEE V WENNERLUND P ERIKSSON LO AASERUD E LEHMUSSAARI J SUOMIN R GABRIEL MA
Citation: Jt. Andersen et al., CAN FINASTERIDE REVERSE THE PROGRESS OF BENIGN PROSTATIC HYPERPLASIA - A 2-YEAR PLACEBO-CONTROLLED STUDY, Urology, 46(5), 1995, pp. 631-637
COMPLICATIONS OF INVASIVE, URODYNAMIC EXAMINATIONS AND PROSTATE BIOPSIES IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Authors: BERGE V ERI LM TVETER KJ
Citation: V. Berge et al., COMPLICATIONS OF INVASIVE, URODYNAMIC EXAMINATIONS AND PROSTATE BIOPSIES IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, Scandinavian journal of urology and nephrology, 1995, pp. 95-98
ALPHA-BLOCKADE IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
Authors: ERI LM TVETER KJ
Citation: Lm. Eri et Kj. Tveter, ALPHA-BLOCKADE IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 154(3), 1995, pp. 923-934
EFFECTS OF THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE ON LIPOPROTEINS, FIBRINOGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Authors: ERI LM URDAL P BECHENSTEEN AG
Citation: Lm. Eri et al., EFFECTS OF THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE ON LIPOPROTEINS, FIBRINOGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 154(1), 1995, pp. 100-104
EFFECTS ON THE ENDOCRINE SYSTEM OF LONG-TERM TREATMENT WITH THE NONSTEROIDAL ANTIANDROGEN CASODEX IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Authors: ERI LM HAUG E TVETER KJ
Citation: Lm. Eri et al., EFFECTS ON THE ENDOCRINE SYSTEM OF LONG-TERM TREATMENT WITH THE NONSTEROIDAL ANTIANDROGEN CASODEX IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, British Journal of Urology, 75(3), 1995, pp. 335-340
SAFETY, SIDE-EFFECTS AND PATIENT ACCEPTANCE OF THE ANTIANDROGEN CASODEX IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Authors: ERI LM TVETER KJ
Citation: Lm. Eri et Kj. Tveter, SAFETY, SIDE-EFFECTS AND PATIENT ACCEPTANCE OF THE ANTIANDROGEN CASODEX IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, European urology, 26(3), 1994, pp. 219-226
SAFETY, SIDE-EFFECTS AND PATIENT ACCEPTANCE OF THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE IN TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Authors: ERI LM TVETER KJ
Citation: Lm. Eri et Kj. Tveter, SAFETY, SIDE-EFFECTS AND PATIENT ACCEPTANCE OF THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE IN TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 152(2), 1994, pp. 448-452
A PROSPECTIVE, PLACEBO-CONTROLLED STUDY OF THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE AS TREATMENT FOR PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Authors: ERI LM TVETER KJ
Citation: Lm. Eri et Kj. Tveter, A PROSPECTIVE, PLACEBO-CONTROLLED STUDY OF THE LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST LEUPROLIDE AS TREATMENT FOR PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 150(2), 1993, pp. 359-364
A PROSPECTIVE, PLACEBO-CONTROLLED STUDY OF THE ANTIANDROGEN CASODEX AS TREATMENT FOR PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Authors: ERI LM TVETER KJ
Citation: Lm. Eri et Kj. Tveter, A PROSPECTIVE, PLACEBO-CONTROLLED STUDY OF THE ANTIANDROGEN CASODEX AS TREATMENT FOR PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA, The Journal of urology, 150(1), 1993, pp. 90-94
Risultati: 1-14 |